Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Portfolio Pulse from
Enanta Pharmaceuticals (ENTA) reported a Q1 loss of $1.05 per share, which is better than the Zacks Consensus Estimate of a $1.16 loss. This is an improvement from the $1.58 loss per share reported a year ago.
February 10, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enanta Pharmaceuticals reported a Q1 loss of $1.05 per share, beating the Zacks Consensus Estimate of a $1.16 loss. This marks an improvement from the previous year's $1.58 loss per share.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to have a positive short-term impact on ENTA's stock price. The improvement from the previous year's loss also suggests positive momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100